An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorHerst, C. V.-
Autor(es): dc.creatorBurkholz, S.-
Autor(es): dc.creatorSidney, J.-
Autor(es): dc.creatorSette, A.-
Autor(es): dc.creatorHarris, P. E.-
Autor(es): dc.creatorMassey, S.-
Autor(es): dc.creatorBrasel, T.-
Autor(es): dc.creatorCunha-Neto, E.-
Autor(es): dc.creatorRosa, D. S.-
Autor(es): dc.creatorChao, W. C. H.-
Autor(es): dc.creatorCarback, R.-
Autor(es): dc.creatorHodge, T.-
Autor(es): dc.creatorWang, L.-
Autor(es): dc.creatorCiotlos, S.-
Autor(es): dc.creatorLloyd, P.-
Autor(es): dc.creatorRubsamen, R.-
Data de aceite: dc.date.accessioned2026-02-09T11:43:19Z-
Data de disponibilização: dc.date.available2026-02-09T11:43:19Z-
Data de envio: dc.date.issued2020-05-27-
Data de envio: dc.date.issued2020-05-27-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41247-
Fonte completa do material: dc.identifierhttp://www.sciencedirect.com/science/article/pii/S0264410X20305181-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1145991-
Descrição: dc.descriptionThe 2013–2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within SARS-CoV-2 contain multiple Class I epitopes with predicted HLA restrictions consistent with broad population coverage. A similar approach to a CTL vaccine design may be possible for that virus.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceVaccine-
Palavras-chave: dc.subjectEbola Zaire vaccine-
Palavras-chave: dc.subjectCTL vaccine-
Palavras-chave: dc.subjectController-
Palavras-chave: dc.subjectYQVNNLEEI-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectFlow focusing-
Título: dc.titleAn effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.